[{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kwality Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kwality Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kwality Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kwality Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Erythropoietin","moa":"EPO receptor","graph1":"Hematology","graph2":"Preclinical","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwality Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kwality Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Kwality Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 02, 2025

                          Lead Product(s) : Losartan Potassium

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Tamoxifen is a small molecule acts as an Estrogen receptor modulator, which is being investigated for the treatment of hormone receptor-positive breast cancer.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 23, 2024

                          Lead Product(s) : Tamoxifen Citrate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Luprodex (leuprorelin acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer.

                          Product Name : Luprodex

                          Product Type : Peptide

                          Upfront Cash : Not Applicable

                          November 07, 2024

                          Lead Product(s) : Leuprolide Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank